Sung-Soo Park

Quick facts

Phase 2 pipeline

• Antibody-Drug Conjugate · Oncology
  Antibody-drug conjugates target specific cancer cells by binding to a protein on the cell surface, delivering a toxic payload to kill the cell.
• Bispecific antibody · Oncology
  Binds to CD16A and CD19 to activate antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Sung-Soo Park portfolio CI brief
• Sung-Soo Park pipeline updates RSS